AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. QGEN
10. ELV

Go back to AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients

AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform

November 9, 2015 9:36 AM EST

Leerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.

Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More